Ozenoxacin Brand Name– XEPI
What is Ozenoxacin
Ozenoxacin is a topical quinolone antimicrobial indicated for the treatment of impetigo due to Staphylococcus aureus (including MRSA) or Streptococcus pyogenes.
Systemic absorption of ozenoxacin is negligible; therefore, systemic adverse events are expected to be limited.
Ozenoxacin is approved for use in adults and in pediatric patients as young as 2 months.
Ozenoxacin was FDA-approved in December 2017.
Indications
- impetigo
- Staphylococcus aureus (MRSA)
- Staphylococcus aureus (MSSA)
- Streptococcus pyogenes (group A beta-hemolytic streptococci)
Side Effects
- superinfection
Rosacea and seborrheic dermatitis were reported in 1 adult patient treated with ozenoxacin in clinical trials (n = 362).
Prolonged use of antimicrobials, such as ozenoxacin, may lead to overgrowth of non-susceptible pathogens or superinfection.
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- pregnancy
Interactions
There are no drug interactions associated with Ozenoxacin products.
